SREBF1 and posterior cortical atrophy: The present study demonstrated that darolutamide decreases SREBP1 expression to inhibit fatty acid synthase (FASN) transcription, which induces lipid peroxidation and ferroptosis onset, leading to suppression of PCa tumorigenesis.